Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-14T02:25:50.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the estimated enrollment for the study evaluating the safety and efficacy of pembrolizumab versus placebo as adjuvant therapy in participants with hepatocellular carcinoma and complete radiological response after surgical resection or local ablation.
    Difference
    0.0%
    Check dated 2024-06-06T15:58:46.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. Previously, this section had no information provided.
    Difference
    14%
    Check dated 2024-05-22T12:33:25.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:34:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.